Pasithea Therapeutics Corp. (KTTAW) Profit After Tax (2021 - 2026)

Pasithea Therapeutics has disclosed Profit After Tax across 6 years of filings, most recently posting -$5.3 million for Q2 2026.

• In Q2 2026, Profit After Tax fell 42.47% year-over-year to -$5.3 million; the TTM figure through Jun 2026 stood at -$21.3 million (down 58.39% YoY), while the FY2025 annual figure was -$20.4 million, down 46.89% from the prior year.
• Profit After Tax came in at -$5.3 million for Q2 2026 at Pasithea Therapeutics, down from -$2.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.6 million in Q1 2022 to a low of -$10.1 million in Q4 2025.
• Average Profit After Tax over 5 years is -$4.0 million, with a median of -$3.7 million recorded in 2023.
• Year-over-year, Profit After Tax sank 899.19% in 2022 and surged 37.57% in 2024.
• Over 5 years, Profit After Tax stood at -$5.0 million in 2022, then fell by 1.27% to -$5.0 million in 2023, then surged by 37.57% to -$3.1 million in 2024, then plunged by 221.03% to -$10.1 million in 2025, then jumped by 47.64% to -$5.3 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$5.3 million in Q2 2026, -$2.9 million in Q1 2026, and -$10.1 million in Q4 2025.